Contribution: Industrial Research Assistance Program – Contributions to Firms
PEARKO Therapeutics Inc.
$295,500.00
Development of Novel Apelin Analog Drugs for Treatment of Cardiovascular Diseases
EF 2021-22 · 2021-11-01
Résumé
PEARKO Therapeutics has been developing ApelinPlus (apelin analog) which can be a treatment for cardiovascular diseases. Currently, we are conducting preclinical testing of ApelinPlus, establishing required procedures, and preparing for regulatory filings with Health Canada, the Food and Drug Administration (FDA), and the European Medicines Agency (EMA).
Ministère
Programme
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (lien de confiance élevée)
Bénéficiaire
Emplacement
Edmonton|Edmonton, Alberta, Canada
Type de bénéficiaire
For-profit organization
Numéro d'entreprise
824764641
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Modifications
Chaque version de l'entente telle que publiée, de la plus ancienne à la plus récente, avec son total à cette version. Le montant ci-dessus est le plus récent.
| Modification | Date | Exercice financier | Total |
|---|---|---|---|
| 0 | 2021-11-01 | 2021-22 | $400,000.00 |
| 1 | 2021-11-01 | 2021-22 | $295,500.00 |
| 2 | 2021-11-01 | 2021-22 | $295,500.00 |
Tel que publié
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 122 days.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 122 jours.
Agreement End Date
2024-03-31
Agreement Number
980844
Agreement Start Date
2021-11-01
Agreement Title
Development of Novel Apelin Analog Drugs for Treatment of Cardiovascular Diseases
Agreement Title (French)
Développement de nouveaux médicaments analogues de l'apeline pour le traitement des maladies cardiovasculaires
Agreement Type
Contribution
Agreement Value
$295,500.00
Amendment Date
2022-12-19
Amendment Number
2
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
PEARKO Therapeutics has been developing ApelinPlus (apelin analog) which can be a treatment for cardiovascular diseases. Currently, we are conducting preclinical testing of ApelinPlus, establishing required procedures, and preparing for regulatory filings with Health Canada, the Food and Drug Administration (FDA), and the European Medicines Agency (EMA).
Description (French)
PEARKO Therapeutics a développé ApelinPlus (analogue de l'apeline) qui peut être un traitement pour les maladies cardiovasculaires. Actuellement, nous effectuons des tests précliniques sur ApelinPlus, établissons les procédures requises et préparons les dépôts réglementaires auprès de Santé Canada, de la Food and Drug Administration (FDA) et de l'Agence européenne des médicaments (EMA).
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Edmonton Riverbend
Federal Riding (French)
Edmonton Riverbend
Federal Riding Number
48018
NAICS Code
541710
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
824764641
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
PEARKO Therapeutics Inc.
Recipient Postal Code
T6R 3A5
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2021-2022-Q3-980844
